Systemic messenger RNA as an etiological treatment for acute intermittent porphyria …………… Jiang L, Berraondo P, Jericó D, Guey LT, Sampedro A, Frassetto A, Benenato KE, Burke K, Santamaría E, Alegre M, Pejenaute Á, Kalariya M, Butcher W, Park JS, Zhu X, Sabnis S, Kumarasinghe ES, Salerno T, Kenney M, Lukacs CM, Ávila MA, Martini…
Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes …………… Veiga N, Goldsmith M, Granot Y, Rosenblum D, Dammes N, Kedmi R, Ramishetti S, Peer D. Nat Commun. 2018 Oct 29;9(1):4493. PubMed 00
Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1 …………… Pirie E, Ray S, Pan C, Fu W, Powers AF, Polikoff D, Miller CM, Kudrna KM, Harris EN, Lusis AJ, Crooke RM, Lee RG. PLoS Genet. 2018 Oct…
Therapeutic Oligonucleotides: State of the Art …………… Smith CIE, Zain R. Annu Rev Pharmacol Toxicol. 2018 Oct 4. PubMed 00